Senores Pharmaceuticals sets Q1 FY27 call on July 27, 2026

Earnings call timing and what it covers

Senores Pharmaceuticals Limited will hold an earnings conference call on July 27, 2026, to discuss its unaudited consolidated and standalone financial results for the quarter ended June 30, 2026. The call is scheduled to begin at 05:15 PM IST. For investors, this is the company’s first structured interaction for Q1 FY27, giving a forum to review reported performance and clarify items in the financial statements.

The company has said it will publish an audio recording and a transcript of the call on its official website after the event. This post-call disclosure is positioned as part of the company’s compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which focuses on timely dissemination of material information.

Management and facilitator details

The discussion will be led by senior management, including Mr. Swapnil Shah (Promoter and Managing Director) and Mr. Sanjay Majmudar (Chairman). Mr. Deval Shah (Whole-Time Director and Chief Financial Officer) will also participate and address queries related to the financial statements.

The conference call is being facilitated by DAM Capital Advisors Ltd. The analyst leading the session is Nitin Agarwal, as per the company’s communication.

How to join: dial-in access and joining guidance

Senores Pharmaceuticals has provided universal access numbers for participants across networks and countries. It has also released region-specific toll-free numbers for international participants, including Hong Kong, Singapore, the UK, and the USA.

Participants have been advised to dial in at least 5 to 10 minutes prior to the scheduled start time to ensure a timely connection.

Universal access numbers: +91 22 6280 1384 or +91 22 7115 8285.

Postal ballot: IPO proceeds variation and other approvals

Separately, Senores Pharmaceuticals has published a postal ballot notice in newspapers to seek shareholder approval for a variation in utilisation of unutilised IPO proceeds amounting to ₹65.016 crore (₹650.16 million). The company is also seeking approval for material related party transactions (RPTs) aggregating ₹754 crore.

The postal ballot notice also includes a proposal to enhance limits for loans and guarantees under Sections 185 and 186 of the Companies Act, 2013. The voting window begins on July 05, 2026, and ends on August 03, 2026.

What changes in the IPO proceeds plan

The Board of Directors, based on the recommendation of the Audit Committee, approved a proposal to reallocate the unutilised IPO proceeds originally earmarked for setting up a sterile injections facility in Atlanta. The company said the unutilised amount of ₹65.016 crore will be redirected towards:

• funding the acquisition of Abbreviated New Drug Applications (ANDAs) by its subsidiary Senores Pharmaceuticals Inc. (SPI)
• capital expenditure for subsidiaries Apnar Pharma Private Limited and Havix Group Inc., doing business as Aavis Pharmaceuticals

The revised utilisation timelines extend to Q4 of FY 2028.

Postal ballot schedule at a glance

The company has laid out the voting schedule and the cut-off date in its notice.

Stock and valuation markers cited ahead of results

Ahead of the July-August 2026 results season window referenced for Q1 FY27, Senores Pharmaceuticals shares were cited as trading at ₹1,382. The same snapshot also cited a market capitalisation of ₹6,356 crore and a price-to-earnings (P/E) multiple of 52.3.

The article data also listed a Q1 FY27 estimate range for revenue and profit after tax (PAT), along with target ranges attributed to “Uniresearch estimate.” These are presented as expectations and targets, not company guidance.

Financial base points and recent reported numbers

The Q1 FY27 estimates referenced were described as being built on a Q1 FY26 base of ₹141 crore revenue and ₹21 crore net profit, and on the most recent year-on-year growth signal from Q4 FY26. For Q4 FY26, the most recent reported quarter in the provided material, revenue was cited at ₹193 crore and net profit at ₹37 crore.

The same dataset also included additional reported figures: revenue from operations in Q4 FY26 of ₹175.19 crore, total income in Q4 FY26 of ₹182.86 crore, and FY26 revenue from operations of ₹632.63 crore. Total income for FY26 was cited at ₹679.69 crore. Separately, an investor presentation highlight cited income of ₹189.7 crore for Q4 FY26 and ₹664.0 crore for FY26, noting that “total income” in the media release may include other operating income.

Key numbers investors are tracking (estimates and history)

The following table consolidates the key metrics explicitly cited in the provided material.

Market impact: what these events change in the near term

For markets, the immediate impact is informational rather than operational. The July 27 earnings call sets a defined time for management commentary, which can help investors reconcile differences across reported lines such as revenue from operations, total income, and presentation highlights.

The postal ballot matters because it seeks shareholder approval for reallocating IPO proceeds away from a planned sterile injections facility in Atlanta, toward ANDA acquisition funding and subsidiary capex. It also brings additional governance items to a vote, including material RPT approvals and higher limits for loans and guarantees under the Companies Act sections cited in the notice.

Why this matters: governance plus quarterly transparency

The combination of an earnings call and a postal ballot creates two parallel checkpoints for stakeholders. The earnings call focuses on Q1 FY27 performance for the quarter ended June 30, 2026. The postal ballot focuses on capital allocation and approval frameworks that can shape how the company deploys capital through the extended timeline stated as up to Q4 FY 2028.

Both items are structured disclosures aligned to SEBI’s Regulation 30 framework referenced by the company. For shareholders, the key is that management is committing to publish an audio recording and transcript after the call, and that the fund utilisation change is being routed through a shareholder approval process with a defined e-voting window.

Conclusion

Senores Pharmaceuticals has scheduled a Q1 FY27 earnings conference call for 05:15 PM IST on July 27, 2026, with senior management and DAM Capital facilitating. In parallel, shareholders are being asked to vote between July 05 and August 03, 2026, on a ₹65.016 crore IPO proceeds reallocation, ₹754 crore of material RPT approvals, and enhanced limits for loans and guarantees, with revised utilisation timelines extending to Q4 FY 2028.